<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LIALDA- mesalamine tablet, delayed release </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LIALDA safely and effectively. See full prescribing information for LIALDA.<br>	LIALDA<span class="Sup">®</span> (mesalamine) delayed-release tablets, for oral use	<br><br>Initial U.S. Approval: 1987</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Interference with Laboratory Tests (5.6), 08/2013 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LIALDA is a locally acting 5-aminosalicylic acid (5-ASA) indicated for the induction of remission in adults with active, mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and for the maintenance of remission of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. (<span class="Underline">
                              1
                           </span>)  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For induction of remission of active, mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, two to four 1.2 g tablets taken once daily with food. (<span class="Underline">
1</span>, <span class="Underline">
                              2</span>)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">For maintenance of remission of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, two 1.2 g tablets taken once daily with food. (<span class="Underline">
1</span>, <span class="Underline">
2</span>)  (<a href="#section-2">2</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Delayed-Release Tablets: 1.2 g (<span class="Underline">
3</span>)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates or aminosalicylates or to any of the ingredients of LIALDA tablets. (<span class="Underline">
4</span>)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> may occur.  Assess renal function at the beginning of treatment and periodically during treatment.  (<span class="Underline">
        5.1</span>)</li>
<li>Mesalamine-induced acute intolerance syndrome has been reported.  Observe patients closely for worsening of these symptoms while on treatment.  (<span class="Underline">
5.2</span>) </li>
<li>Use caution when treating patients who are hypersensitive to sulfasalazine.  (<span class="Underline">
5.3</span>)</li>
<li>Mesalamine-induced cardiac <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>) have been reported.  (<span class="Underline">
5.3</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> has been reported in patients with pre-existing liver disease. Use caution when treating patients with liver disease.  (<span class="Underline">
5.4</span>)</li>
<li>Upper <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">GI tract obstruction</span> may delay onset of action. (<span class="Underline">
5.5</span>)</li>
<li>Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. (5.6)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk"><li>The most common adverse reactions (incidence ≥ 2%) are <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, liver function test abnormality, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.  (<span class="Underline">
6.1</span>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Shire US Inc. at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Nephrotoxic agents including NSAIDs: renal reactions have been reported. (<span class="Underline">
7.1</span>)</li>
<li>Azathioprine or 6-mercaptopurine: <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> have been reported. (<span class="Underline">
7.2</span>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:  Use LIALDA with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. (<span class="Underline">
5.1</span>, <span class="Underline">
7.1</span>, <span class="Underline">
8.5</span>, <span class="Underline">
13.2</span>)</li>
<li>Nursing Women: Caution should be exercised when administered to a nursing woman. (<span class="Underline">
8.3</span>)</li>
<li>Geriatric Patients: Monitor blood cell counts in geriatric patients. (<span class="Underline">
8.5</span>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Mesalamine-Induced Acute Intolerance Syndrome</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Upper <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">GI Tract Obstruction</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Interference with Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Azathioprine or 6-mercaptopurine</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Active, Mild to Moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Maintenance of Remission in Patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LIALDA is indicated for the induction of remission in patients with active, mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and for the maintenance of remission of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage for the induction of remission in adult patients with active, mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> is two to four 1.2 g tablets taken once daily with a meal for a total daily dose of 2.4 g or 4.8 g. The recommended dosage for the maintenance of remission is two 1.2 g tablets taken once daily with a meal for a total daily dose of 2.4 g.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">The red-brown ellipsoidal delayed-release tablet containing 1.2 g mesalamine is debossed on one side and imprinted with S476.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LIALDA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates or aminosalicylates or to any of the ingredients of LIALDA <span class="Italics">[see </span><span class="Italics">
Warnings and Precautions (5.3)
</span>, <span class="Italics">Description (11)
                     </span>, <span class="Italics">
Adverse Reactions (6.2)
                     </span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including minimal change <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, acute and <span class="product-label-link" type="condition" conceptid="4177206" conceptname="Tubulointerstitial nephritis">chronic interstitial nephritis</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has been reported in patients given products such as LIALDA that contain mesalamine or are converted to mesalamine.</p>
<p>It is recommended that patients have an evaluation of renal function prior to initiation of LIALDA therapy and periodically while on therapy. Exercise caution when using LIALDA in patients with known renal dysfunction or a history of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
<p>In animal studies, the kidney was the principal organ for toxicity. <span class="Italics">[See </span><span class="Underline"><span class="Italics">Drug Interactions (7.1)
                              </span></span><span class="Italics"> and </span><span class="Underline"><span class="Italics">
Nonclinical Toxicology (13.2)</span></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2	Mesalamine-Induced Acute Intolerance Syndrome</h2>
<p class="First">Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.  Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine.  Symptoms include cramping, acute <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and sometimes <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  Observe patients closely for worsening of these symptoms while on treatment.  If acute intolerance syndrome is suspected, promptly discontinue treatment with LIALDA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Some patients who have experienced a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to sulfasalazine may have a similar reaction to LIALDA tablets or to other compounds that contain or are converted to mesalamine.</p>
<p>Mesalamine-induced cardiac <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>) have been reported with LIALDA and other mesalamine medications.  Caution should be taken in prescribing this medicine to patients with conditions predisposing them to the development of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients with pre-existing liver disease who have been administered mesalamine.  Caution should be exercised when administering LIALDA to patients with liver disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5	Upper <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">GI Tract Obstruction</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">Pyloric stenosis</span> or other organic or functional obstruction in the upper gastrointestinal tract may cause prolonged gastric retention of LIALDA which would delay mesalamine release in the colon.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6	Interference with Laboratory Tests</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and mesalamine's main metabolite, N-acetylaminosalicylic acid (N-Ac-5-ASA). An alternative, selective assay for normetanephrine should be considered.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions seen in Lialda clinical trials or with other products that contain or are metabolized to mesalamine are:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> <span class="Italics">[See <span class="Underline">
  Warnings and Precautions (5.1)</span>]</span>
</li>
<li>Mesalamine-induced acute intolerance syndrome <span class="Italics">[See <span class="Underline">
Warnings and Precautions (5.2)</span>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <span class="Italics">[See <span class="Underline">
Warnings and Precautions (5.3)</span>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> <span class="Italics">[See <span class="Underline">
Warnings and Precautions (5.4)
                           </span>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>LIALDA has been evaluated in 1368 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients in controlled and open-label trials.</p>
<p><span class="Underline">Induction of Remission</span></p>
<p>In two 8-week placebo-controlled clinical trials involving 535 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients, 356 received 2.4 g/day or 4.8 g/day LIALDA tablets and 179 received placebo. The most frequent adverse reaction leading to discontinuation from LIALDA therapy was exacerbation of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> (0.8%). <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> occurred in less than 1% of patients during clinical trials and resulted in discontinuation of therapy with LIALDA in patients experiencing this event.</p>
<p>Adverse reactions occurring in LIALDA or placebo groups at a frequency of at least 1% in two 8-week, double blind, placebo-controlled trials are listed in Table 1. The most common adverse reactions with LIALDA 2.4 g/day and 4.8 g/day were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.6% and 3.4%, respectively) and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (4% and 2.8%, respectively).</p>
<p><span class="Bold">Table 1: Adverse Reactions in Two Eight-Week Placebo-Controlled Trials Experienced by at Least 1% of the LIALDA Group and at a Rate Greater than Placebo<span class="Sup">a</span></span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Adverse<br>Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">LIALDA<br>2.4 g/day<br>(n = 177)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">LIALDA<br>4.8 g/day<br>(n = 179)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br><br>(n = 179)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 (5.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (3.4%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (4%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5 (2.8%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5 (2.8%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver Function Test Abnormal</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  1 (0.6%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  4 (2.2%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2 (1.1%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  0 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2 (1.1%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  1 (0.6%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2 (1.1%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2 (1.1%) </td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="4">  a: Adverse reactions for which the placebo rate equalled or exceeded the rate for at least one of the LIALDA treatment groups were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </td></tr>
</tbody>
</table>
<p>The following adverse reactions, presented by body system, were reported infrequently (less than 1%) by LIALDA-treated <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients in the two controlled trials.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorder</span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">prurigo</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4216644" conceptname="Rectal polyp">rectal polyp</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">Investigations:</span> decreased platelet count</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics">General Disorders and Administrative Site Disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span></p>
<p><span class="Underline">Maintenance of Remission of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></span></p>
<p>The dose evaluated in three studies of LIALDA given for the maintenance of remission in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> was 1.2 g twice daily or 2.4 g/once daily. One of these studies was a 6-month double-blind comparator study while two were 12- to 14-month open-label studies.</p>
<p>The most common adverse reactions with LIALDA in the maintenance arms of long-term trials were <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">colitis ulcerative</span> (5.8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.9%), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span> (2.3%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2.2%). Of the 1082 subjects in the all maintenance studies pooled, 1.9% had severe adverse reactions. The most common severe adverse reactions were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>; these were mainly symptoms associated with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p><span class="Bold">Table 2: Adverse Reactions in Three Maintenance Trials Experienced by at Least 1% of the LIALDA Group (maintenance phases of trials)</span>  </p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> <br> <span class="Bold">All LIALDA<br>(n=1082)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Adverse<br> Reaction</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> %</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Colitis ulcerative</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  63  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (5.8%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  31  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (2.9%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Liver function test abnormal   </td>
<td class="Botrule Lrule Rrule Toprule" align="center">   25   </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (2.3%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  24  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (2.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  18  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.7%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  14  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.3%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  13  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  13  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  13  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  13  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.2%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  12  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.1%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  11  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.0%) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  10  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (1.0%) </td>
</tr>
</tbody>
</table>
<p>The following adverse reactions, presented by body system, were reported infrequently (less than 1%) by LIALDA-treated <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients in the three long-term maintenance trials (maintenance phases of these trials):</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorder</span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, pruritis, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4216644" conceptname="Rectal polyp">rectal polyp</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics">General Disorders and Administrative Site Disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to the adverse reactions reported above in clinical trials involving LIALDA, the adverse reactions listed below have been identified during post-approval use of LIALDA and other mesalamine-containing products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Body as a Whole:</span> lupus-like syndrome, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span></p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4206466" conceptname="Peptic ulcer with hemorrhage AND perforation">perforated peptic ulcer</span></p>
<p><span class="Italics">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, Kawasaki-like syndrome including changes in liver enzymes</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS)</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: </span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Italics">Neurological/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, Guillain-Barre syndrome, transverse <span class="product-label-link" type="condition" conceptid="138965" conceptname="Myelitis">myelitis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disorders</span>:</span> interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> (including <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, allergic alveolitis, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>)</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="133283" conceptname="Pyoderma gangrenosum">pyoderma gangrenosum</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span></p>
<p><span class="Italics">Urogenital:</span> reversible <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">No investigations of interaction between LIALDA and other drugs  except for certain antibiotics have been performed <span class="Italics">[see Pharmacokinetics (12.3)]</span>. However, the following drug-drug interactions have been reported for products containing mesalamine:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs</h2>
<p class="First">The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of renal reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2	Azathioprine or 6-mercaptopurine</h2>
<p class="First">The concurrent use of mesalamine with azathioprine or 6-mercaptopurine may increase the risk for <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Pregnancy Category B.  Reproduction studies with mesalamine have been performed in rats at doses up to 1000 mg/kg/day (1.8 times the maximum recommended human dose based on a body surface area comparison) and rabbits at doses up to 800 mg/kg/day (2.9 times the maximum recommended human dose based on a body surface area comparison) and have revealed no evidence of impaired fertility or harm to the fetus due to mesalamine.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Mesalamine is known to cross the placental barrier.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Low concentrations of mesalamine and higher concentrations of its N-acetyl metabolite have been detected in human breast milk.  The clinical significance of this has not been determined and there is limited experience of nursing women using mesalamine.  Caution should be exercised if LIALDA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of LIALDA in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, i.e., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> in patients who were 65 years or older who were taking mesalamine-containing products such as LIALDA. Caution should be taken to closely monitor blood cell counts during mesalamine therapy.</p>
<p>Clinical trials of LIALDA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic exposures are increased in elderly subjects. <span class="Italics">[see <span class="Underline">
Clinical Pharmacology (12.3)
                              </span>]</span>. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy in elderly patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">LIALDA is an aminosalicylate, and symptoms of salicylate toxicity may include <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> may lead to disruption of electrolyte balance and blood-pH, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, and end organ damage.</p>
<p>There is no specific known antidote for mesalamine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; however, conventional therapy for salicylate toxicity may be beneficial in the event of acute overdosage.  Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be corrected by the administration of appropriate intravenous therapy.  Adequate renal function should be maintained.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Each LIALDA delayed-release tablet for oral administration contains 1.2 g 5-aminosalicylic acid (5-ASA; mesalamine), an anti-inflammatory agent. Mesalamine also has the chemical name 5-amino-2-hydroxybenzoic acid and its structural formula is:</p>
<p><img alt="lialda-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21&amp;name=lialda-01.jpg"></p>
<p>Molecular formula: C<span class="Sub">7</span>H<span class="Sub">7</span>NO<span class="Sub">3</span></p>
<p>Molecular weight: 153.14</p>
<p>The tablet is coated with a pH dependent polymer film, which breaks down at or above pH 6.8, normally in the terminal ileum where mesalamine then begins to be released from the tablet core. The tablet core contains mesalamine with hydrophilic and lipophilic excipients and provides for extended release of mesalamine.</p>
<p>The inactive ingredients of LIALDA are sodium carboxymethylcellulose, carnauba wax, stearic acid, silica (colloidal hydrated), sodium starch glycolate (type A), talc, magnesium stearate, methacrylic acid copolymer types A and B, triethylcitrate, titanium dioxide, red ferric oxide and polyethylene glycol 6000.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of mesalamine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, and it is possible that mesalamine diminishes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.</p>
<p>Mesalamine has the potential to inhibit the activation of nuclear factor kappa B (NFκB) and consequently the production of key pro-inflammatory cytokines. It has been proposed that reduced expression of PPARγ nuclear receptors (γ-form of peroxisome proliferator-activated receptors) may be implicated in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. There is evidence that mesalamine produces pharmacodynamic effects through direct activation of PPARγ receptors in the colonic/rectal epithelium.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">The pharmacodynamic actions of mesalamine occur in the colonic/rectal mucosae local to the delivery of drug from LIALDA into the lumen.  There is information suggesting that severity of colonic <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients treated with mesalamine is inversely correlated with mucosal concentrations of mesalamine.  Plasma concentrations representing systemically absorbed mesalamine are not believed to contribute extensively to efficacy.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>The total absorption of mesalamine from LIALDA 2.4 g or 4.8 g given once daily for 14 days to healthy volunteers was found to be approximately 21-22% of the administered dose. </p>
<p>Gamma-scintigraphy studies have shown that a single dose of LIALDA 1.2 g (one tablet) passed intact through the upper gastrointestinal tract of fasted healthy volunteers. Scintigraphic images showed a trail of radio-labeled tracer in the colon, suggesting that mesalamine had distributed through this region of the gastrointestinal tract.</p>
<p>In a single dose study, LIALDA 1.2 g, 2.4 g and 4.8 g were administered in the fasted state to healthy subjects. Plasma concentrations of mesalamine were detectable after 2 hours and reached a maximum by 9-12 hours on average for the doses studied. The pharmacokinetic parameters are highly variable among subjects (Table 3). Mesalamine systemic exposure in terms of area under the plasma concentration-time curve (AUC) was slightly more than dose proportional between 1.2 g and 4.8 g LIALDA. Maximum plasma concentrations (C<span class="Sub">max</span>) of mesalamine increased approximately dose proportionately between 1.2 g and 2.4 g and sub-proportionately between 2.4 g and 4.8 g LIALDA, with the dose normalized value at 4.8 g representing, on average, 74% of that at 2.4 g based on geometric means.</p>
<p><span class="Bold">Table 3: Mean (SD) PK Parameters for Mesalamine Following Single Dose Administration of LIALDA Under Fasting Conditions</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Parameter<span class="Sup">1</span> of Mesalamine</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">LIALDA 1.2 g<br>(N=47)</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">LIALDA 2.4 g<br>(N=48)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">LIALDA 4.8 g<br>(N=48)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  AUC<span class="Sub">0-t</span> (ng.h/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  9039<span class="Sup">+</span> (5054) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  20538 (12980) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  41434 (26640) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  AUC<span class="Sub">0-∞</span> (ng.h/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  9578<span class="Sup">•</span> (5214) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  21084 (13185) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  44775<span class="Sup">#</span> (30302) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  C<span class="Sub">max</span> (ng/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  857 (638) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  1595 (1484) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2154 (1140) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  T<span class="Sub">max</span>* (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  9.0** (4.0-32.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  12.0 (4.0-34.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  12.0 (4.0-34.0) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  T<span class="Sub">lag</span>* (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.0** (0-8.0) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.0 (1.0-4.0) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.0 (1.0-4.0) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  T<span class="Sub">1/2</span> (h) (Terminal Phase) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  8.56<span class="Sup">•</span> (6.38) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  7.05<span class="Sup">§</span> (5.54) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  7.25<span class="Sup">#</span> (8.32) </td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="4"> <span class="Sup">1</span> Arithmetic mean of parameter values are presented except for T<span class="Sub">max</span> and T<span class="Sub">lag</span>.<br>*Median (min, max); <span class="Sup">+</span>N=43, <span class="Sup">•</span>N=27, <span class="Sup">§</span>N=33, <span class="Sup">#</span>N=36, **N=46 </td></tr>
</tbody>
</table>
<p>Administration of a single dose of LIALDA 4.8 g with a high fat meal resulted in further delay in absorption, and plasma concentrations of mesalamine were detectable 4 hours following dosing. However, a high fat meal increased systemic exposure of mesalamine (mean C<span class="Sub">max</span>: ↑ 91%; mean AUC: ↑ 16%) compared to results in the fasted state. LIALDA was administered with food in the controlled clinical trials that supported its approval.</p>
<p>In a single and multiple dose pharmacokinetic study of LIALDA, 2.4 g or 4.8 g was administered once daily with standard meals to 28 healthy volunteers per dose group. Plasma concentrations of mesalamine were detectable after 4 hours and were maximal by 8 hours after the single dose. Steady state was achieved generally by 2 days after dosing. Mean AUC at steady state was only modestly greater (1.1- to 1.4-fold) than predictable from single dose pharmacokinetics.</p>
<p>In a single dose pharmacokinetic study of LIALDA, 4.8 g was administered in the fasted state to 71 healthy male and female volunteers (28 young (18-35yrs); 28 elderly (65-75yrs); 15 elderly (&gt;75yrs)). Increased age resulted in increased systemic exposure (approximately 2-fold in C<span class="Sub">max</span>), to mesalamine and its metabolite N-acetyl-5-aminosalicylic acid. Increased age resulted in a slower apparent elimination of mesalamine, though there was high between-subject variability. Systemic exposures in individual subjects were inversely correlated with renal function as assessed by estimated creatinine clearance.</p>
<p><span class="Bold">Table 4: Mean (SD) PK Parameters for Mesalamine Following Single Dose Administration of LIALDA 4.8 g under Fasting Conditions to Young and Elderly Subjects</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Parameter of 5-ASA</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Young Subjects<br>(18-35 yrs)<br>(N=28)</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"> Elderly Subjects<br>(65-75 yrs)<br>(N=28)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Elderly Subjects<br>(&gt;75 yrs)<br>(N=15)</span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  AUC<span class="Sub">0-t</span> (ng.h/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  51570 (23870) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  73001 (42608) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  65820 (25283) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  AUC<span class="Sub">0-∞</span> (ng.h/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  58057<span class="Sup">b</span> (22429) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  89612<span class="Sup">c</span> (40596) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  63067<span class="Sup">d</span> (22531) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  C<span class="Sub">max</span> (ng/mL) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2243 (1410) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  4999 (4381) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  4832 (4383) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  t<span class="Sub">max</span><span class="Sup">a</span> (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  22.0 (5.98 - 48.0) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  12.5 (4.00 - 36.0) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  16.0 (4.00 - 26.0) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  t<span class="Sub">lag</span><span class="Sup">a</span> (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.00 (1.00 - 6.00) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.00 (1.00 - 4.00) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.00 (2.00 - 4.00) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  t<span class="Sub">1/2</span> (h), terminal phase </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  5.68<span class="Sup">b</span> (2.83) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  9.68<span class="Sup">c</span> (7.47) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  8.67<span class="Sup">d</span> (5.84) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  Renal clearance (L/h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.05 (1.33) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.04 (1.16) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.13 (1.20) </td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="4">  Arithmetic mean (SD) data are presented, N = Number of subjects<br><span class="Sup">a</span> Median (min-max), <span class="Sup">b</span>N=15, <span class="Sup">c</span>N=16, <span class="Sup">d</span>N=13 </td></tr>
</tbody>
</table>
<p><span class="Italics">Distribution</span></p>
<p>Mesalamine is approximately 43% bound to plasma proteins at the concentration of 2.5 μg/mL.</p>
<p><span class="Italics">Metabolism</span></p>
<p>The only major metabolite of mesalamine (5-aminosalicylic acid) is N-acetyl-5-aminosalicylic acid. Its formation is brought about by N-acetyltransferase (NAT) activity in the liver and intestinal mucosa cells, principally by NAT-1.</p>
<p><span class="Italics">Elimination</span></p>
<p>Elimination of mesalamine is mainly via the renal route following metabolism to N-acetyl-5-aminosalicylic acid (acetylation). However, there is also limited excretion of the parent drug in urine. Of the approximately 21-22% of the dose absorbed, less than 8% of the dose was excreted unchanged in the urine after 24 hours, compared with greater than 13% for N-acetyl-5-aminosalicylic acid. The apparent terminal half-lives for mesalamine and its major metabolite after administration of LIALDA 2.4 g and 4.8 g were, on average, 7-9 hours and 8-12 hours, respectively.</p>
<p><span class="Italics">Drug Interactions:</span></p>
<p>The potential effect of Lialda (4.8 g given once daily) on the pharmacokinetics of four commonly used antibiotics were evaluated in healthy subjects.  The four antibiotics studied and their dosing regimens were as follows:  amoxicillin (single 500 mg dose), ciprofloxacin XR (single 500 mg dose), metronidazole (750 mg twice daily for 3.5 days), and sulfamethoxazole/trimethoprim (800 mg/160 mg twice daily for 3.5 days).  Coadministration of Lialda did not result in clinically significant changes in the pharmacokinetics of any of the four antibiotics.  The change in Cmax and AUC of amoxicillin, ciprofloxacin and metronidazole when they were co-administered with Lialda were all ≤ 3%.  There was an increase of 12% in Cmax and an increase of 15% in AUC of sulfamethoxazole when sulfamethoxazole/trimethoprim was coadministered with Lialda <span class="Italics">[see <a href="#LINK_f07b60fd-8540-420e-b2fe-3edc2c5cba9a">Drug Interactions (7)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>In a 104-week dietary carcinogenicity study in CD-1 mice, mesalamine at doses up to 2500 mg/kg/day was not tumorigenic.  This dose is 2.2 times the maximum recommended human dose (based on a body surface area comparison) of LIALDA.  Furthermore, in a 104-week dietary carcinogenicity study in Wistar rats, mesalamine up to a dose of 800 mg/kg/day was not tumorigenic.  This dose is 1.4 times the recommended human dose (based on a body surface area comparison) of LIALDA.</p>
<p><span class="Italics">Mutagenesis</span></p>
<p>No evidence of mutagenicity was observed in an <span class="Italics">in vitro</span> Ames test or an<span class="Italics"> in vivo</span> mouse micronucleus test.</p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>No effects on fertility or reproductive performance were observed in male or female rats at oral doses of mesalamine up to 400 mg/kg/day (0.7 times the maximum recommended human dose based on a body surface area comparison).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">In animal studies with mesalamine, a 13-week oral toxicity study in mice and 13-week and 52-week oral toxicity studies in rats and cynomolgus monkeys have shown the kidney to be the major target organ of mesalamine toxicity.  Oral daily doses of 2400 mg/kg in mice and 1150 mg/kg in rats produced renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, <span class="product-label-link" type="condition" conceptid="194994" conceptname="Renal infarction">renal infarct</span>, papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">tubular necrosis</span>, and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.  In cynomolgus monkeys, oral daily doses of 250 mg/kg or higher produced <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, papillary <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Active, Mild to Moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">Two similarly designed, randomized, double blind, placebo-controlled trials were conducted in 517 adult patients with active, mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. The study population was primarily Caucasian (80%), had a mean age of 42 years (6% age 65 years or older), and was approximately 50% male. Both studies used LIALDA doses of 2.4 g/day and 4.8 g/day administered once daily for 8 weeks except for the 2.4 g/day group in Study 1, which was given in two divided doses (1.2 g twice daily). The primary efficacy end-point in both trials was to compare the percentage of patients in remission after 8 weeks of treatment for the LIALDA treatment groups versus placebo. Remission was defined as an <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> Disease Activity Index (UC-DAI) of ≤ 1, with scores of zero for <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> and for stool frequency, and a sigmoidoscopy score reduction of 1 point or more from baseline.</p>
<p>In both studies, the LIALDA doses of 2.4 g/day and 4.8 g/day demonstrated superiority over placebo in the primary efficacy endpoint (Table 5). Both LIALDA doses also provided consistent benefit in secondary efficacy parameters, including clinical improvement, treatment failure, clinical remission, and sigmoidoscopic improvement. LIALDA 2.4 g/day and 4.8 g/day had similar efficacy profiles.</p>
<p><span class="Bold">Table 5: Patients in Remission at Week 8</span></p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"> Dose</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Study 1<br>(n=262)<br>n/N (%)</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"> Study 2<br>(n=255)<br>n/N (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  LIALDA 2.4 g/day </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  30/88 (34.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  34/84 (40.5) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">  LIALDA 4.8 g/day </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  26/89 (29.2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  35/85 (41.2) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">  Placebo </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  11/85 (12.9) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  19/86 (22.1) </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2	Maintenance of Remission in Patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">A multicenter, randomized, double-blind, active comparator study was conducted in a total of 826 adult patients in remission from <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.  The study population had a mean age of 45 years (8% age 65 years or older), were 52% male, and were primarily Caucasian (64%).</p>
<p>Maintenance of remission was assessed using a modified <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> Disease Activity Index (UC-DAI).  For this trial, maintenance of remission was based on maintaining endoscopic remission defined as a modified UC-DAI endoscopy subscore of ≤1.  An endoscopy subscore of 0 represented normal mucosal appearance with intact vascular pattern and no friability or granulation.  For this trial the endoscopy score definition of 1 (mild disease) was modified such that it could include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, decreased vascular pattern, and minimal granularity; however, it could not include friability.</p>
<p>Subjects were randomized in a 1:1 ratio to receive either LIALDA 2.4 g/day administered once daily or mesalamine delayed release 1.6 g/day administered as 0.8 g twice daily.  The proportion of patients who maintained remission at Month 6 in this study using LIALDA 2.4 g once daily (83.7%) was similar to that seen using the comparator (mesalamine delayed release) 1.6 g/day (81.5%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">LIALDA is available as red-brown ellipsoidal film coated delayed-release tablets containing 1.2 g mesalamine, and debossed on one side imprinted with S476.</p>
<p>NDC 0179-0142-70 Box of 30 Delayed-Release Unit Dose Tablets.</p>
<p>Store at room temperature 15<span class="Sup">°</span>C to 25<span class="Sup">°</span>C (59<span class="Sup">°</span>F to 77<span class="Sup">°</span>F); excursions permitted to 30<span class="Sup">°</span>C (86<span class="Sup">°</span>F).</p>
<p>See USP Controlled Room Temperature.</p>
<p>REPACKAGED BY:</p>
<p>KAISER FOUNDATION HOSPITALS</p>
<p>LIVERMORE, CA 94551</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disk">
<li>Instruct patients not to take LIALDA if they have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates (e.g., aspirin) or other mesalamines.</li>
<li>Inform patients to let their physicians know all medications they are taking and if they: <ul class="Circle">
<li>are allergic to sulfasalazine, salicylates or mesalamine;</li>
<li>are taking non-steroidal anti-inflammatory drugs (NSAIDs) or other nephrotoxic agents;</li>
<li>are taking azathioprine, or 6-mercaptopurine;</li>
<li>experience cramping, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>;</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>;</li>
<li>have kidney or liver disease;</li>
<li>have a history of stomach blockage;</li>
<li>are pregnant, intend to become pregnant or are breast-feeding.</li>
</ul>
</li>
<li>Patients should be instructed to swallow LIALDA delayed-release tablets whole, taking care not to break the outer coating.</li>
</ul>
<p class="First">Manufactured for Shire US Inc., 725 Chesterbrook Blvd., Wayne, PA 19087, USA by Cosmo S.p.A., Milan, Italy. By license of Nogra Pharma Limited, Dublin, Ireland.</p>
<p>U.S. Patent No. 6,773,720.</p>
<p>© 2013 Shire US Inc. </p>
<p>REPACKAGED BY:</p>
<p>KAISER FOUNDATION HOSPITALS</p>
<p>LIVERMORE, CA 94551</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>NDC 0179-0142-70 - 1.2g BOX OF 30 UNIT DOSE </h1>
<div class="Figure">
<img alt="lialda-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21&amp;name=lialda-02.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LIALDA 		
					</strong><br><span class="contentTableReg">mesalamine tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0142(NDC:54092-476)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MESALAMINE</strong> (MESALAMINE) </td>
<td class="formItem">MESALAMINE</td>
<td class="formItem">1.2 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red) , BROWN (brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">S476</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0142-70</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022000</td>
<td class="formItem">12/06/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack(0179-0142)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5d64a942-c06b-4182-9b7d-eb29e910d4a7</div>
<div>Set id: 07e5ac9c-a5b2-42dc-84fa-963dbc51ba21</div>
<div>Version: 1</div>
<div>Effective Time: 20131206</div>
</div>
</div> <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
